Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study of TAGraxofusp and Azacitidine with or Without Venetoclax in Newly Diagnosed Secondary AML After Previous Exposure to HypOmethylatiNG Agents

Next Previous
X
Search
Trial Profile

Phase II Study of TAGraxofusp and Azacitidine with or Without Venetoclax in Newly Diagnosed Secondary AML After Previous Exposure to HypOmethylatiNG Agents

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Mar 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine (Primary) ; Tagraxofusp (Primary)
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes; Myeloproliferative disorders
  • Focus Therapeutic Use
  • Acronyms TAGALONG

    • Most Recent Events

    • 23 Apr 2024 Status changed from not yet recruiting to recruiting.
    • 03 Apr 2024 Planned initiation date changed from 1 Mar 2024 to 1 Apr 2024.
    • 01 Feb 2024 Planned initiation date changed from 1 Dec 2023 to 1 Mar 2024.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top